SCHEMBL21608043

SCHEMBL21608043

CCOC(=O)c1cnc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)n1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.39
SYK P43405 1/20 0.38
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
LMNA P02545 3/20 0.35
ESR1 P03372 1/20 0.35
MAPT P10636 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
GABRA1 P14867 1/20 0.33
CYP2C19 P33261 1/20 0.33
GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24275808 0.77 SYK (0.38) SYKNFKB1NFKB2RELALMNA
SCHEMBL24275860 0.74 GAA (0.40) SYKNFKB1NFKB2RELALMNA
SCHEMBL28720076 0.73 IDO1 (0.45) IDO1LMNAMAPTSMN1; SMN2NPC1
SCHEMBL4735920 0.72 CYP3A4 (0.41) SYKLMNAMAPTSMN1; SMN2NPC1
SCHEMBL15052607 0.72 ALDH1A1 (0.38) SYKNFKB1NFKB2RELAMAPT
SCHEMBL465766 0.71 SYK (0.47) SYKLMNAESR1MAPTSMN1; SMN2
SCHEMBL20077493 0.71 NTRK1 (0.46) NFKB1NFKB2RELAMAPTSMN1; SMN2
SCHEMBL998243 0.70 IDO1 (0.43) IDO1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL28616856 0.70 IDO1 (0.47) IDO1LMNAMAPTSMN1; SMN2NPC1
SCHEMBL1979899 0.70 CSNK1D (0.49) IDO1LMNAMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022053010-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2022-03-17 WO disclosed
WO-2019243531-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed